Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.44 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977418 | 0.94 | ELANE (0.47) | ELANEF2KDM1AUSP28USP25 | |
| SCHEMBL23640978 | 0.86 | ELANE (0.53) | ELANEF2USP28USP25RAB9A | |
| SCHEMBL22918273 | 0.85 | KDM1A (0.46) | KDM1ARAB9ASMN1; SMN2NPC1CCR5 | |
| SCHEMBL29661076 | 0.85 | KDM1A (0.46) | KDM1ARAB9ASMN1; SMN2NPC1CCR5 | |
| SCHEMBL31611455 | 0.84 | RAB9A (0.48) | ELANEF2KDM1AUSP28USP25 | |
| SCHEMBL1539239 | 0.83 | ELANE (0.50) | ELANEF2USP28USP25RAB9A | |
| SCHEMBL20521874 | 0.83 | KDM1A (0.48) | KDM1ARAB9ASMN1; SMN2NPC1MRGPRX4 | |
| SCHEMBL30221893 | 0.83 | KDM1A (0.48) | KDM1ARAB9ASMN1; SMN2NPC1MRGPRX4 | |
| SCHEMBL22918085 | 0.82 | KDM1A (0.43) | KDM1ARAB9ASMN1; SMN2PTGER1 | |
| SCHEMBL29660949 | 0.82 | KDM1A (0.43) | KDM1ARAB9ASMN1; SMN2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114616226-B | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20220235006-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Enterprise Therapeutics Limited (GB) | 2022-07-28 | — | — | US | disclosed |
| CN-114616226-A | Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders | TMEM16A有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021014166-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Enterprise Therapeutics Limited (GB) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235006-A1 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | TMEM109, TMEM70, TMEM120A | ELANE 3148/4885F2 4789/4885KDM1A 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.